Provided by Tiger Trade Technology Pte. Ltd.

BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

273.02
-1.7150-0.62%
Volume:4.32K
Turnover:1.18M
Market Cap:30.30B
PE:110.53
High:273.51
Open:272.64
Low:271.58
Close:274.73
52wk High:385.22
52wk Low:196.45
Shares:111.00M
Float Shares:85.58M
Volume Ratio:0.54
T/O Rate:0.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.47
EPS(LYR):2.47
ROE:7.46%
ROA:3.96%
PB:6.95
PE(LYR):110.53

Loading ...

BeOne Medicines Initiated at Buy by Truist Securities

Dow Jones
·
Nov 25, 2025

BeOne Medicines initiated with a Buy at Truist

TIPRANKS
·
Nov 24, 2025

Beone Medicines : Truist Securities Initiates Coverage With Buy Rating; Target Price $400

THOMSON REUTERS
·
Nov 24, 2025

BEIGENE Opens Over 3% Higher in Early Trading; CSCI Maintains "Buy" Rating

Deep News
·
Nov 18, 2025

HK Stock Movement | BEIGENE (06160) Opens Over 3% Higher as Phase 3 Clinical Study of Zanidatamab Combined with Tislelizumab and Chemotherapy Shows Positive Results

Stock News
·
Nov 18, 2025

BEIGENE (06160) Grants 16,500 Restricted Share Units in the Form of ADS

Stock News
·
Nov 14, 2025

Stock Track | BeiGene Shares Soar 5.03% Following Strong Q3 Financial Results and Turnaround to Profitability

Stock Track
·
Nov 12, 2025

Beigene (688235.SH) Reports Q1-Q3 Results: Net Profit Attributable to Shareholders at RMB1.139 Billion, Turning Loss into Profit YoY

Stock News
·
Nov 12, 2025

BEIGENE Surges Over 6% in Early Trading as Zanubrutinib Exceeds Expectations in US and European Markets

Deep News
·
Nov 12, 2025

BEIGENE (06160) Zanubrutinib Sales in US and Europe Exceed Expectations; Haitong International Maintains "Outperform" Rating

Stock News
·
Nov 11, 2025

Barclays Sticks to Its Buy Rating for BeOne Medicines (ONC)

TIPRANKS
·
Nov 10, 2025

Stock Track | BeOne Medicines (ONC) Soars 5.07% on Strong Q3 Earnings, Raised Guidance

Stock Track
·
Nov 07, 2025

BEIGENE (06160) Q3 Revenue Surpasses RMB 10 Billion, Raises Full-Year Guidance

Stock News
·
Nov 06, 2025

BeOne Medicines AG reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Nov 06, 2025

GUIDANCE: (ONC) BeOne Medicines Expects Full Year 2025 Sales Range $5.1B - $5.3B, vs. FactSet Est of $5.22B

MT Newswires Live
·
Nov 06, 2025

BeOne Medicines AG expected to post earnings of 78 cents a share - Earnings Preview

Reuters
·
Nov 04, 2025

How Positive Phase 3 Lung Cancer Results at BeOne Medicines (ONC) Have Changed Its Investment Story

Simply Wall St.
·
Oct 28, 2025

BeOne Medicines Advances Phase 3 Study for CLL/SLL Treatment

TIPRANKS
·
Oct 28, 2025

BeOne Medicines’ Tislelizumab Study: A Potential Game-Changer for MSI-H/dMMR Tumors

TIPRANKS
·
Oct 28, 2025

China's NMPA Grants Breakthrough Therapy Designation for Anti-CTLA-4 Antibody Candidate Gotistobart (BNT316/ONC-392)

prnewswire
·
Oct 27, 2025